Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Folks trying to bash down the stock?
It is the same one person bashing this stock daily.
What is his motive????
We have a lot of $$$$ invested in this stock and it a shame basher or bashers show up on company that has drugs that may provide hope for so many people. Yes all penny stocks have diluting and yes many of these stock still run hard.
This stock has a history long term history of run hard out of nowhere. I am holding and waiting.
I am still here holding a lot of shares. I got others that have been running so i just leave these idle waiting for the next run.
Other stocks that ran lately were just out of the blue and ran up.
Just buy people. - Jeff
Yep.
And for sure there is risk that their candidate drug programs fail at some point in preclinicals; but they genuinely seem enthusiastic and confident given other preclinical efforts and experiences. Considering new VP gets paid at .0015 restricted, recent institutional investor absorbed debt, pushed out to early 2025 and reduced rate to 0%, plus other stakeholders lining up with preferred shares requiring a major payment event to see any ROI at all and then the CEO comments about hoping to open "purse strings" while completing tier 3 NIH preclinicals, hints at where this could be going.
I agree in that when any BP deal is struck, this will be driven by huge money outside IHUB realm, and will be an immediate rocket ship. Given how undervalued the base price is situated, this has that potential to be one stories are told about.
I agree completely....
If there was ever a setup this, is it. Very low volume and PPS at depressed levels (vastly undervalued). I can point to other stocks with much higher (multiples) market caps with a fraction of the potential. All good for me and for the patient. I like getting in on bottoms. This is NOT a IHUB trading stock. This is a big money stock that will be moved by NON IHUB investors. If we haven't already been found with accumulation from weak retail selling, we soon will be imho.
As much as many would not like to hear this. When it is time, THEY WILL DECIDE when it leaves these levels. Honestly the more bashing and whining is a good sign.
Almost ALL of my biggest winners reacted this same way. Under the radar slow accumulation, folks trying to bash down a stock already beaten down to almost silliness levels with minimal volume.
Patience is key!
LMAO as the volume sits at a big fat 0....
I always thought stock message forums were valuable avenues to discuss potential in an investment, what is plausible, where is the risk, deciphering the progress or lack thereof; but wtf do I know.
I personally like the risk v. reward. Risk is of course there is zero progress, the stock flounders at these levels or lower indefinitely. Reward potential is they have preclinical success, strike BP development deals and stock trades at nickels and dimes. Worth my gambling.. er.... speculative money.
Jeff would like to thank you. You are very a important part of the distribution process. -Jeff
IMO, the pharma business in general is a speculation or some would call it a "gamble".. The odds of successfully progressing through development, preclinicals and then Phase 1,2,3 clinicals are low. However, with each successful passing in the various stages of development the value increases,sometimes dramatically. At what point are the bigger pharmas engaged and negotiating development deals, exclusive rights, buyouts? I think the answer is at each and every stage...
Short answer easily found by looking at their filings is that RSPI is the opposite of "sufficiently funded". They need resources to move forward.
I think if their epilepsy/pain drug candidate completes the robust preclinicals of the NIH and is positioned for grant money into human trials, then there is something of very significant value there that big pharma will want in on now before moving into human clinicals. Especially considering the high profile nature of the opioids epidemic.
The OSA program seems to have less risk on the safety aspect of re-purposing dronabinol, moreso on will the new formulations successfully extend the duration of effect while maintaining minimal side effects. Assumption is they are in preclincals there as well with a quicker passage through human trials, less cost to develop. Plus a current estimated valuation around 20 million which nowhere near shows up in the market cap here at the moment.
Amazing to me that some legit IP and legit progress in the pharma world can trade less than a million in valuation while many OTC gambles are sitting at 10x that value with much less prospects or business potential. I think what the gamblers here are seeing is that there is a legit possibility for major BP dealings here that can shoot valuations into the 100's millions similar to past storied pharma stocks. And the potential here would likely have much more sticking power, IMO
GLTA.
Funny to see all the gamblers here... when you are done here, look up GA... never too late
Very possible!!! i would take anything over $1.00 but do believe with this company's pipeline that we could see a buyout offer come in at $4.25, this would set the stage for a rally up to $5.00/ share and then instituitional buyers like Baker Bros Advisors LLC to purchase 15% of the float.
(there is nothing wrong with having Faith in your hopes) :) <*(( ))><
Buy Out for $3.00 would be nice:)
Sorry, all. I asked roughly the same thing a while back. Pardon my repetition.
Do not all BP risk losing out to THE BP that buys this all sooner than later in its more speculative status...or is RSPI sufficiently funded and staffed to reject offers until they have an fda approved, analyst recommended, gargantuan?...if anyone knows or cares to speculate?
Exactly.
They have progressed into tier 3 preclinicals with the NIH to mitigate the opioid epidemic. This positive progression is valuable and important. It is only logical that monied interests and big pharma are watching these trials closely. IMO, if these trials confirm their past preclinical observations that lead into human clinicals, than the sky is the limit as to how valuable this drug development program has become.... IMO.
Agreed!
When you least expect it it will pop.
Honestly that's the best way for it to happen. When it is least expected. 👍️
I have been adding some on the dips. Holding tight. Some retail is getting shaken.
Market Cap: 697,214 (Seriously???) LOL
imho worth minimum dirt cheap at 10 million Market Cap.
That is always the case. They are all a POS until they are Not!
They will release Big News when nobody expects it.
I got my popcorn ready for RSPI!
When you least expect it it will pop.Nice buying for an uptick yesterday.
Thank You! I am holding a nice position here, but I want more! LOL I know this one is just a matter of time.
If I can get some more profits on others I will add to my position here.
I’m still here with you as well. I’m holding all the ones that I still think will pop! I’m playing crypto as well, so not as active in the pennies as I normally would be. Best of luck my friend…
Jeff is mad! Come on folks step up and average down. -J
Exactly, thank you for your support. -Jeff
P.S. please don't forget to avg down and help a brotha out.
Not the recent transaction but countless over many years achieving absolutely nothing other than investors loosing money.
Statements like this, again reinforce the level of ignorance on this entire board.
The proceeds from each of the transactions, do not go to the company.
This is not a secondary, or private placement, or IPO etc, etc...
SMH
If its gambling then its a bad bet, always have been always will be imo. But the guys behind the operation continues to live fine of of other people’s money.
This is gambling and not investing.
Looking for...
10-K update to see any tidbits on improving debt/convertibles and restructuring them as they have for other stakeholders already who appear to be lining up with expectations of major progress sooner than later.
The SCI/ADHD is essentially on hold pending funding according to recent PR.
This leaves the OSA program, which hoping to hear an update as to if preclinicals on new formulations are underway, prepping for IND/human clincals???
Any update on tier 3 trials with NIH and "loosening pursestrings". IMO this progress/candidate is legitimately a really big deal and any and all commentary related to the candidate is enthusiastically positive. Obviously no guarantees, but I would have to imagine discussions with big pharma are underway already. With each phase, tier, preclincial... showing positive, the value increases for the IP. Hence, why some here have the opinion that "any day", is the current thesis. GLTA.
I suppose when anyone has so much time equity into a particular stock you are an investor byg default whether your persuasion is more in than out or vice versa.
Still agreeing with you on this one.
"Investors" LOL! - J
Sure there has definitely been some conversions, but all news has been rather vanilla with a passive approach and minimal follow-up. I would think investors would be interested in timelines, next steps/milestones, NIH path and success implications, OSA program updates, funding status/efforts etc, etc.
Although maybe the "short-term loosen purse strings" comment is alluding to their current focus and efforts....
I disagree, Jeff has been increasing the float to the best of his abilities.
Considering all the positive traction with their drug candidates, they are not doing a very good job of what you suggest.... if that is the intent...
Well,
IMO, RSPI can be much more potent and lucrative. Advancing through robust NIH preclinicals and all the positive studies completed with epilepsy and pain.... just feels like this is a really big pharma deal, not simply OTC type of deal...
I'm sure that Jeff is comitted to adressing the float issue.
Right on DTGoody. RSPI gonna be great
I am still here, and I will not go Anywhere!!! This will be the next RGBP in my opinion. That ran from .002 to .08 cents in three days with 3.5 Billion shares in the Float.
Just like RGBP ran after it got its Big Pharma Partnership, so will RSPI run when we get our Big Pharma Partnership Announcement.
Unlike RGBP with it's tradable float of 3.5 Billion with a 5 Billion OS, our RSPI entire AS is only @ 2 Billion shares.
RSPI is the easiest buy and hold for me:
Outstanding Shares
774,682,161
04/02/2024
Held at DTC or (Tradable Float)
728,897,301
04/02/2024
Averaging down is critical with RSPI. You must always average down - J
RSPI going to be huge sharky
good time to average down. the only thing that could ruin this is the infamous Reverse Split, which fortunately, has not been mentioned as of yet. LONG AND STRONG, adding at these levels could possibly yield a great ROI glta
Spot on Sharky!
No approved drug available yet for this. The alternative treatments presently are uncomfortable, and I believe I had read a few weeks back could have links to cancer.
We are in the proverbial sweet spot for several breakthroughs imho.
Patience!
Dronabinol, a synthetic version of ?-9-THC, a naturally occurring substance in the cannabis plant, has already demonstrated significant improvement in the symptoms of OSA in two phase 2 clinical trials. OSA impacts an estimated 29.4 million people in the United States and has been linked to increased risk for hypertension, heart failure, depression, and diabetes. There are no approved drug treatments for OSA.
$RSPI
Yeah, it would only be logical that a drug candidate that has progressed extremely positively in the NIH preclinicals would already have engagement with big pharma. Purpose of the new hire 4 months ago? Assumption is they are in tier 3 preclinicals now with NIH, no timeline given to complete, but CEO mentioned loosinenig "pursestrings" in the short term. Really it could happen any day, I suppose. One would think all parties including NIH would want to see success rolled immediately into or ASAP into human clinical trials.
I can only assume the OSA program is underway with preclinical trials as well, but no update there for quite some time.
This is the OTC, so speculative money only, but personally I love the risk v. reward potential here. GLTA.
Have a good friend…
Battling to get off opioids. It’s been a struggle with migraines as a result. Trying to do it right. If Pharma’s have potential solution these folks need to get off their multi billion dollar pocket books and get some real solutions out there!!!
It’s coming imho. Huge high exposure will begin to drive this up and hopefully get things rolling for the folks needing help!!
Glad to be a part of the solution!!
Notice of Late Filing
https://www.otcmarkets.com/filing/html?id=17417768&guid=J1Q-karWJBwfJth
Many of these sub penny stocks are filing late.
The good thing is they are filing!
Good morning all, our eggs will hatch in time.
$RSPI
Agree in a sense that the company really hasnt provided any input recently as to milestones/targets, expectations, etc. Couple that with the convertible debt that needs to be mitigated, then I suppose it explains the fledgling stock. The only thing mentioned in recent press is hoping to find financing to advance the SCI/ADHD program later this year.
That leaves the OSA program, which has some funding set up in Australia and presumably conducting some pre-clinicals on new formulations?
And the pain/epilepsy candidate in NIH tier 3 trials, presumably underway but no idea when to expect results?
And CEO hoping to open "pursestrings" now with very positive preclinical data in hand.
Feels like very significant irons in the fire that when/if pulled out will be white hot. Just no idea on timing. Hoping 10-K will shed some insight.
GLTA.
Followers
|
347
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
51992
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
Form Type | Received | Period End Date | Report |
---|---|---|---|
8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |